
Entresto Is Top HFrEF Treatment Recommendation in Updated ACC Guidelines
Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.
Treatment optimization for
One focus of the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction is optimizing HFrEF treatment through expanded use of
“New therapies for HFrEF have emerged that expand the armamentarium for the treatment of patients with HFrEF since the original Pathway was published in 2017,” noted the ECDP authors
While Entresto, which is part of the angiotensin receptor-neprilysin inhibitor (ARNI) class of HF therapies, is already indicated for use among patients with chronic HF, this update also expands treatment with Entresto to include patients with de novo, or new-onset, HF—a first for the combination neprilysin inhibitor (sacubitril) and angiotensin II receptor blocker (ARB; valsartan).
Concomitant use of Entresto with an angiotensin-converting enzyme (ACE) inhibitor or ARB
The ARNI class is one of several new treatments—along with sodium-glucose cotransporter-2 inhibitors and percutaneous therapy for mitral regurgitation—that have emerged since the 2017 ECDP to innovate the treatment landscape for HFrEF, noted the authors, prompting the present update.
The ACC report, considered interim guidance, also incorporates “the considerable impact of the coronavirus disease 2019 (COVID-19) pandemic on outpatient management of chronic disease states such as HFrEF,” along with coverage of these 10 fundamental issues:
- Initiating, adding, or switching to new therapies for HFrEF
- Achieving optimal therapy
- Referring patients to an HF specialist
- Addressing care coordination
- Improving treatment adherence
- Addressing specific patient cohorts:
African Americans , the elderly, and thefrail - Managing patients’ medication costs and access
- Managing complex HF
- Managing common comorbidities
- Integrating
palliative care and transitioning to hospice care
Additional
In seeking to become the first FDA-approved medication to treat patients who have HF with preserved ejection fraction (HFpEF), Entresto went up for
Reference
Maddox TM, Januzzi JL Jr, Allen LA, et al; Writing Committee. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. Published online January 4, 2021. doi:10.1016/j.jacc.2020.11.022
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.